Loading stock data…
$9.28-0.53 (-5.40%)
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
ClearPoint Neuro, Inc. in the Healthcare sector is trading at $9.36 with a market capitalization of $285M. Wall Street consensus targets $23.50 (2 analysts), implying a +151.2% move over the next 12 months. The stock is currently near its 52-week low of $8.27, remaining 29.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.88M↓ | $12.13M↑ | $10.41M↑ | $8.86M↓ | $9.21M |
| Gross Profit | $6.71M↓ | $7.76M↑ | $6.40M↑ | $5.60M↑ | $5.56M |
| Operating Income | -$10.24M↓ | -$8.48M↓ | -$7.04M↓ | -$5.28M↑ | -$5.68M |
| Net Income | -$11.34M↓ | -$9.55M↓ | -$7.79M↓ | -$5.89M↓ | -$5.84M |
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint sy...